Latest News
Endo initiates Phase 2b study of collagenase clostridium histolyticum for cellulite treatment
Endo International has started its Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of edematous fibrosclerotic panniculopathy, commonly known as...
Eisai and PIQUR to investigate Halaven and PQR309 in triple-negative breast cancer
Eisai and PIQUR Therapeutics are to conduct a Phase 1/2b clinical study to investigate PQR309 combined with Halaven (eribulin) in triple-negative breast cancer (TNBC)...
Boehringer and Eli Lilly present Jardiance study results for type 2 diabetes
Boehringer Ingelheim and Eli Lilly have presented positive top-line results of Jardiance (empagliflozin) from the EMPA-REG OUTCOME study in type 2 diabetes patients at high risk of...
Celtaxsys receives FDA approval to begin acebilustat’s trial of CF
Clinical-stage pharmaceutical development firm Celtaxsys has received approval from the US Food and Drug Administration (FDA) to start a Phase II clinical trial of its drug candidate,...
Oryx completes VicOryx Phase I/IIa trial for HPV-associated cancers
Translational medicine firm Oryx has completed a Phase I/IIa trial of the therapeutic vaccine VicOryx to treat p16INK4a-overexpressing Human Papilloma Virus (HPV) positive cancer...
Rock Creek seeks regulatory approval to start clinical trials for Anatabine Citrate
Drug development firm Rock Creek Pharmaceuticals is seeking regulatory approval to start clinical trials for the continued development of its Anatabine Citrate lead molecule in the...
Roche to discontinue Phase III study of gantenerumab in early Alzheimer’s disease
Swiss drugmaker Roche has announced its plans to discontinue SCarlet RoAD (WN25203), a Phase III study of investigational anti-amyloid medicine gantenerumab in prodromal (pre-dementia)...
GSK's Phase III trial of shingles vaccine candidate meets primary endpoint
GlaxoSmithKline (GSK) has reported that its Phase III trial designed to evaluate the efficacy of HZ/su, an investigational vaccine for the prevention of shingles, met its primary...
Pfizer enrols first patient in Phase II trial of PF-06252616 to treat DMD
Pfizer has enrolled the first patient in its multicentre Phase II clinical trial of PF-06252616, an experimental, infused, anti-myostatin monoclonal antibody, to treat boys with Duchenne...
Synthetic Biologics doses first patient in Phase Ia clinical trial of SYN-004
Synthetic Biologics has dosed the first patient in a Phase Ia clinical trial of SYN-004, an investigational oral beta-lactamase enzyme, to preventi Clostridium difficile (C. difficile)...
Polaris begins ADI-PEG 20 Phase I trial for advanced pancreatic cancer
Polaris Group has started dosing patients in its Phase I trial of ADI-PEG 20 in combination with nab-paclitaxel and gemcitabine to treat advanced pancreatic...
Vaximm reports positive result from trial extension of oral cancer vaccine
Swiss-German biotech company biotech company Vaximm has announced follow-on data from the first clinical trial of its investigational oral T-cell vaccine...
Ocular completes patient enrolment in two Phase III trials of dexamethasone
US-based biopharmaceutical firm Ocular Therapeutix has completion patient enrolment in two of its Phase III clinical trials evaluating sustained release dexamethasone (OTX-DP) to treat...
GSK’s Stiefel begins subcutaneous ofatumumab Phase III trial for pemphigus vulgaris
British drug maker GlaxoSmithKline’s (GSK) subsidiary Stiefel has commenced Phase III trial to assess the efficacy and safety of subcutaneous ofatumumab in patients with a rare autoimmune...
Mylan to start Phase III trial of generic Advair Diskus, insulin analogue to Lantus
Global generic and specialty pharmaceuticals company Mylan is set to start a Phase III clinical trial of its generic version of GlaxoSmithKline's (GSK) Advair Diskus and its insulin analogue...
Merck discontinues clinical trials of Tecemotide for lung cancer treatment
Merck Serono has stopped all remaining clinical studies of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (L-BLP25) as a monotherapy in stage III non-small cell...
Avanir reports Phase II data of investigational drug AVP-923 for Alzheimer's disease
Avanir Pharmaceuticals has reported safety and efficacy results from its Phase II clinical trial of its investigational drug AVP-923 in patients with Alzheimer's disease....
Xention begins first Phase II trial of XEN-D0103 to treat atrial fibrillation
UK-based Xention has initiated Phase II trial of XEN-D0103, a potent and selective oral modulator of the cardiac potassium channel Kv1.5, to treat atrial fibrillation (AF)....
Baxter reports top-line results from BAX 855 Phase III clinical trial
Baxter International has reported top-line results from its BAX 855 Phase III clinical trial, which is an investigational and extended half-life recombinant factor VIII (rFVIII) treatment...
Celator enrolls first patient in PK/PD study of CPX-351 liposome injection
US-based Celator Pharmaceuticals has enrolled the first patient in a Phase II pharmacokinetic and pharmacodynamics (PK/PD) study of CPX-351 (cytarabine:daunorubicin) Liposome...
Boehringer enrolls first patients in phase III study to evaluate dabigatran etexilate
Germany-based Boehringer Ingelheim has enrolled the first patients in its new RE-DUAL PCI international phase III study to evaluate dabigatran etexilate in atrial fibrillation (AF) patients...
